Reduction rate of monoclonal protein as a useful prognostic factor in standard-risk group of newly diagnosed multiple myeloma

Figure 1 Kaplan-Meier analysis of progression-free survival of patients with different reduction rates of monoclonal protein after the first cycle of chemotherapy (P < 0. 001). A: Progression-free survival (PFS) of patients with a reduction rate of monoclonal protein (M protein) after first chemotherapy of ≥ 25% vs < 25%; B: PFS of patients with a reduction rate of M protein after first chemotherapy of ≥ 50% vs < 50%. PFS: Progression-free survival.

Figure 2 Kaplan-Meier analysis of progression-free survival of patients with different reduction rates of monoclonal protein after the fourth cycle of chemotherapy (P < 0. 001). A: Progression-free survival (PFS) of patients with a reduction rate of monoclonal protein (M protein) after the fourth chemotherapy cycle of ≥ 25% vs < 25%; B: PFS of patients with a reduction rate of M protein after fourth chemotherapy of ≥ 50% vs < 50%; C: PFS of patients with a reduction rate of M protein after fourth chemotherapy of ≥ 75% vs < 75%. PFS: Progression-free survival.